RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023

Dec 29, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-12-27

Reporting Person: Shulman Joseph (Chief Technical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-27	Common Stock	M	2400	$21.38	Acquired	6141	Direct
2023-12-27	Common Stock	S	5015	$50.0092	Disposed	1126	Direct
2023-12-28	Common Stock	M	6800	$21.38	Acquired	7926	Direct
2023-12-28	Common Stock	S	7926	$50.0023	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-27	Stock Option (Right to Buy)	$21.38	M	2400	Disposed	2030-07-26	Common Stock (2400)	Direct
2023-12-28	Stock Option (Right to Buy)	$21.38	M	6800	Disposed	2030-07-26	Common Stock (6800)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.